| latanoprost / Generic mfg. |
ACTRN12619001464156p: Do latanoprost eye drops alter optic nerve stress signals in eyes with optic disc drusen? |
|
|
| Not yet recruiting | 4 | 16 | | | Jesse Gale, University of Otago Wellington | Optic disc drusen | | | | |
ACTRN12606000265572: Cystoid Macular Edema Associated With Topical Latanoprost in Patients that Underwent Uncomplicated Cataract Surgery |
|
|
| Not yet recruiting | 4 | 20 | | | Federal University of Uberlândia, Federal University of Uberlândia | Cystoid Macular Edema | | | | |
| Ongoing | 4 | 648 | Europe | Xalatan, PhXA41, Eye drops, solution, Latanoprost | Moorfields Eye Hospital | Primary open-angle Glaucoma Pseudoexfoliation Glaucoma, Primary open-angle Glaucoma Pseudoexfoliation Glaucoma, Body processes [G] - Ocular Physiological Phenomena [G14] | | | | |
ChiCTR-OCC-11001326: Association between genetic polymorphism of Prostaglandin-mediated drug enzymes, transporters and receptor and disease susceptibility and response to Latanoprost |
|
|
| Completed | 4 | 220 | | Latanoprost ;Health control | Institute of Clinical Pharmacology, Central South University; Institute of Clinical Pharmacology, Central South University, Self-funding | Glaucoma | | | | |
2013-000581-10: Examining the effects of eye drops on changes in inflammation on the surface of the eye |
|
|
| Ongoing | 4 | 100 | Europe | latanoprost, travaprost, bimatoprost, tafluprost, Timolol maleate, Brimonidine tartrate, Brinzolamide, Dorzolamide hydrochloride, pilocarpine hydrochloride, Pilocarpine nitrate, N/A, Eye drops, solution, Eye drops, , Xalatan, Travatan, Lumigan, Saflutan, Timptol, Trusopt, Pilocarpine hydrochloride, N/A | Nottingham University NHS Trust | Glaucoma is the condition that is being treated by these eye drops - however the study is aimed at measuring the amount of inflammation that develops on the surface of the eye when these drops are used, Diseases [C] - Eye Diseases [C11] | | | | |
2013-001634-17: LONG-TERM 24-HOUR INTRAOCULAR PRESSURE CONTROL AND PROGRESSION RATE OBTAINED WITH THE ASSOCIATION OF COMBIGAN IN THE MORNING AND GANFORT IN THE EVENING COMPARED WITH LATANOPROST IN HIGH RISK OPEN-ANGLE GLAUCOMA. Controllo della pressione intraoculare nelle 24 ore e velocità di progressione della malattia ottenuto con la somministrazione di Combigan al mattino e Ganfort la sera rispetto alla somministrazione di Latanoprost la sera nei pazienti con nuova diagnosi di glaucoma ad angolo aperto o Glaucoma esfoliativo ad alto rischio di progressione. |
|
|
| Ongoing | 4 | 60 | Europe | COMBIGAN, GANFORT, LATANOPROST, LATANOPROST, Eye drops, Ear drops, COMBIGAN COLLIRIO 5 ML, GANFORT 0,3 mg/ml + 5 mg/ml, LATANOPROST | AZIENDA OSPEDALIERA S. PAOLO, Allergan Pharmaceuticals | Patients with glaucoma open angle or glaucoma exfoliative with high risknewly diagnosed and untreated. Pazienti con glaucoma angolo aperto o glauco esfoliativo ad alto rischio con nuova diagnosi e non trattati., Patients with glaucoma open angle or glaucoma exfoliative with high risknewly diagnosed and untreated. Pazienti con glaucoma angolo aperto o glauco esfoliativo ad alto rischio con nuova diagnosi e non trattati., Diseases [C] - Eye Diseases [C11] | | | | |
2019-001642-18: Effect on the eye surface when treating glaucoma with eye drops Effekt på øjets overflade ved behandling af grøn stær med øjendråber |
|
|
| Not yet recruiting | 4 | 28 | Europe | Monoprost, Xalatan, Eye drops, Monoprost, Xalatan | Department of Ophthalmology, Rigshospitalet-Glostrup, Department of Ophthalmology, Rigshospitalet-Glostrup | Open angular glaucoma and ocular hypertension, glaucoma and ocular hypertension, Diseases [C] - Eye Diseases [C11] | | | | |
2019-003426-24: 3-months study to evaluate the efficacy and tolerability of the drug tafluprost –timolol without preservatives in people with glaucoma or high pressure in the eyes that have already taken latanoprost with preservative. Studio della durata di 3 mesi per valutare l'efficacia e la tollerabilità del farmaco tafluprost –timololo senza conservanti in persone con glaucoma o pressione alta agli occhi che hanno già assunto latanoprost con conservante. |
|
|
| Ongoing | 4 | 43 | Europe | Loyada, [N/A], Eye drops, solution, LOYADA - "15 MICROGRAMMI/ML + 5 MG/ML COLLIRIO, SOLUZIONE" 30 X 0,3ML CONTENITORI MONODOSE IN LDPE | IRCCS FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA ONLUS, Santen d SA | Glaucoma or ocular hypertension Glaucoma o ipertensione oculare, Glaucoma or high pressure in the eyes Glaucoma o pressione alta negli occhi, Diseases [C] - Eye Diseases [C11] | | | | |
HERO, NCT05299593: 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. |
|
|
| Recruiting | 4 | 43 | Europe | tafluprost/timolol | Fondazione G.B. Bietti, IRCCS | Glaucoma, Open-Angle, Ocular Hypertension | 06/22 | 06/22 | | |
| Completed | 4 | 136 | US | Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Rocklatan® | Aerie Pharmaceuticals | Glaucoma | 03/23 | 03/23 | | |
PRO-122, NCT04702789: Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. |
|
|
| Terminated | 4 | 28 | RoW | Dorzolamide-timolol-brimonidine and latanoprost, PRO-122, Krytantek Ofteno PF®, Gaap Ofteno PF®, Dorzolamide-timolol and latanoprost, Eliptic Ofteno PF® | Laboratorios Sophia S.A de C.V. | Glaucoma, Open-Angle, Ocular Hypertension | 11/23 | 11/23 | | |
NCT04957329: Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells |
|
|
| Recruiting | 4 | 28 | Europe | Xalatan, BAK-preserved latanoprost, Monoprost, Preservative-free latanoprost | Rigshospitalet, Denmark, Laboratoires Thea | Glaucoma, Ocular Hypertension | 12/26 | 12/26 | | |
NCT05606796: Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos. |
|
|
| Recruiting | 4 | 76 | RoW | Latanoprost 0.005% Ophthalmic Solution | Uzoma Chinyei Joan | Effect of Drug | 08/23 | 09/23 | | |
| Recruiting | 4 | 70 | Europe | Preservative-free latanoprost 50µg/ml, Preserved latanoprost 0.005% | Medical University of Vienna | Glaucoma, Ocular Hypertension | 09/23 | 09/23 | | |
NCT04811326: Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation |
|
|
| Active, not recruiting | 4 | 150 | RoW | NB-UVB, narrow band ultraviolet B, Latanoprost, latanoprost eye drops | Shaimaa Fawzy Abdel-rady Abdel-latif | Non-segmental Vitiligo | 02/24 | 03/24 | | |
NCT06449352: Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost |
|
|
| Recruiting | 4 | 100 | US | Netarsudil, Brimonidine | Westlake Eye Specialists, Sengi | Normal Tension Glaucoma | 06/25 | 06/25 | | |
NCT04412096: Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance |
|
|
| Recruiting | 4 | 100 | US | Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution | Ohio State University, University of Nebraska, National Eye Institute (NEI), Mayo Clinic | Glaucoma, OHT - Ocular Hypertension | 05/25 | 08/25 | | |
EVOLVE, NCT06407973: A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma |
|
|
| Terminated | 4 | 2 | US | OMNI Surgical System, OMNI, Latanoprost plus adjunctive glaucoma medication | Sight Sciences, Inc. | Primary Open Angle Glaucoma | 01/25 | 01/25 | | |
2013-000142-19: - ENSAYO CLÍNICO ABIERTO, ALEATORIZADO CON EVALUACIÓN CIEGA POR EL INVESTIGADOR PARA EVALUAR NO INFERIORIDAD DE LATANOPROST 50µg/ml COLIRIO COMPARADO CON XALATAN COLIRIO EN EL TRATAMIENTO DEL GLAUCOMA DE ÁNGULO ABIERTO O DE LA HIPERTENSIÓN OCULAR |
|
|
| Ongoing | 3 | 148 | Europe | Latanoprost, -, Eye drops, solution, Eye drops, solution in single-dose container, XALATAN, Xalatan | VISIOTACT PHARMA, Novocat Farma SA | - TRATAMIENTO DEL GLAUCOMA DE ÁNGULO ABIERTO O DE LA HIPERTENSIÓN OCULAR, - TRATAMIENTO DEL GLAUCOMA DE ÁNGULO ABIERTO O DE LA HIPERTENSIÓN OCULAR, Diseases [C] - Eye Diseases [C11] | | | | |
2007-006674-28: Klinické skúšanie účinnosti a bezpečnosti generického produktu UNILAT v terapii glaukómu a vnútroočnej hypertenzie – non-inferiority štúdia. |
|
|
| Ongoing | 3 | 80 | Europe | UNILAT, XALATAN, XALATAN, XALATAN | UNIMED PHARMA spol. s r. o. | Glaukóm (Glaucoma), vnútroočná hypertenzia (Ocular hypertension) | | | | |
2010-020213-82: Comparison of Incidence and Severity of conjunctival hyperemia associated with use of topical Bimatoprost 0.01% and latanoprost 0.005% in Glaucoma or Ocular Hypertensive patients |
|
|
| Ongoing | 3 | 30 | Europe | lumigan 0.1, XALATAN, lumigan 0.1, XALATAN | IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS | glaucoma or ocular hypertension | | | | |
2010-021456-25: ESTUDIO CLÍNICO DE SEGURIDAD PARA COMPARAR UNA SOLUCIÓN TÓPICA OFTÁLMICA DE GAAP OFTENO® (LATANOPROST AL 0.005%) FRENTE A XALATAN® (LATANOPROST AL 0.005%) COMO PRODUCTO DE REFERENCIA, EN PACIENTES CON GLAUCOMA PRIMARIO DE ANGULO ABIERTO Y/O HIPERTENSIÓN OCULAR. |
|
|
| Ongoing | 3 | 50 | Europe | Latanoprost, XALATAN 0,005%, colirio en solucion, GAAP-Ofteno, XALATAN 0,005%, colirio en solucion, GAAP-Ofteno | Laboratorios SOPHIA, S.A. de C.V. | Pacientes con glaucoma primario de ángulo abierto y/o hipertensión ocular | | | | |
2011-002601-30: A COMPARISON OF LATANOPROST 50µg/ml EYE DROPS vs. XALATAN EYE DROPS IN THE TREATMENT OF OPEN ANGLE GLAUCOMA COMPARACION DE LATANOPROST 50μg/ml COLIRIO vs. XALATAN COLIRIO EN EL TRATAMIENTO DE GLAUCOMA DE ANGULO ABIERTO |
|
|
| Ongoing | 3 | 150 | Europe | Latanoprost, XALATAN, Xalatan, Xalatan | OMNIVISION GmbH, Omnivision GmbH | Open angle glaucoma Glaucoma de ángulo abierto | | | | |
2015-005314-29: Randomized, open-label, two parallel group clinical trial, conducted under blinding evaluator conditions to compare the efficacy and tolerability of preservative-free formulation of Latanoprost 50µg/ml eye drops vs. Xalatan in patients with open-angle glaucoma or hypertension ocular. Ensayo clínico aleatorizado, no enmascarado para el paciente aunque enmascarado para el evaluador, con dos grupos en paralelos, para comparar la eficacia y tolerabilidad del colirio formulado con latanoprost 50µg/ml sin conservantes frente al colirio Xalatan en pacientes con glaucoma de ángulo abierto o hipertensión ocular. |
|
|
| Ongoing | 3 | 126 | Europe | Latanoprost 50 ug/ml, Eye drops, XALATAN | OMNIVISION GmbH, Omnivision GmbH | Open Angle Glaucoma or Ocular Hypertension Glaucoma de ángulo abierto o Hipertensión ocular, Open Angle Glaucoma or Ocular Hypertension Glaucoma de ángulo abierto o Hipertensión ocular, Diseases [C] - Eye Diseases [C11] | | | | |
2018-001727-39: EFFICACY AND TOLERABILITY OF GENERIC LATANOPROST 0.05 MG/ML EYE DROPSSOLUTION (POLPHARMA S.A.) COMPARED TO XALATAN® (LATANOPROST 0.005% OPHTHALMIC SOLUTION, PFIZER) IN PATIENTS WITH OCULARHYPERTENSION OR PRIMARY OPEN ANGLE GLAUCOMA. A generikus latanoprost 0,05 mg/ml oldatos szemcsepp (Polpharma S.A.) és a Xalatan® (latanoprost 0,005 % oldatos szemcsepp, Pfizer) összehasonlító vizsgálata emelkedett szembelnyomású vagy primer nyílt zugú glaucomában szenvedő betegeknél. |
|
|
| Ongoing | 3 | 50 | Europe | generic latanoprost 0.5 mg/mL, preservative free, Xalatan® (Latanoprost 0.005% ophthalmic solution), Eye drops, solution, Xalatan® | Polpharma S.A., Polpharma S.A. | Ocular hypertension and open angle glaucoma, glaucoma zöldhályog, Diseases [C] - Eye Diseases [C11] | | | | |
2020-004307-14: This study will evaluate and confirm that the efficacy and tolerability of anew Preservative-free Generic Formulation of Latanoprost 50μg/ml EyeDrops solution in single dose container is not worse to the marketedpreservative-containing formulation Xalatan®Eye Drops solution in Patients with Open Angle Glaucoma or Ocular Hypertension Η μελέτη θα τεκμηριώσει ότι η αποτελεσματικότητα και ανεκτικότητα ενός νέου γενοσήμου σκευάσματος Λατανοπρόστης 50μg/ml οφθαλμικές σταγόνες σε περιέκτη μιας δόσης χωρίς συντηρητικό δεν είναι κατώτερη από το εγκεκριμένο σκευάσμα Xalatan® οφθαλμικές σταγόνες που περιέχει συντηρητικό σε ασθενείς με Γλαύκωμα Ανοικτής Γωνίας ή Οφθαλμική Υπερτονία |
|
|
| Not yet recruiting | 3 | 170 | Europe | Latanoprost 0.05 mg/mL eye drops, solution in single-dose container, Eye drops, solution in single-dose container, Ear drops, solution, ΧΑLATAN® | actrevo GmbH, actrevo GmbH | Open angle glaucoma or ocular hypertension Elevated IOP and paediatric glaucoma. Γλαύκωμα Ανοικτής Γωνίας ή Ενδοφθάλμια Υπερτονία, Open angle glaucoma is characterized by increased intraocular pressure, resulting in pathological changes in the optic disk and typical visual field defects,and eventually blindness To γλαύκωμα ανοικτής γωνίας χαρακτηρίζεται από αυξημένη ενδοφθάλμια πίεση η οποία έχει ως αποτέλεσμα παθολογικές αλλαγές στον οπτικό δίσκο και τυπικά ελλείμματα του οπτικού πεδίου και τελικώς τύφλωση, Diseases [C] - Eye Diseases [C11] | | | | |
2021-000147-45: A non-inferiority, randomized, investigator - masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost (YSLT) versus a reference drug (Xalatan®) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) – The COMET Study Μια μη-κατωτερότητας, τυχαιοποιημένη, τυφλή ως προς τον ερευνητή, δύο παράλληλων ομάδων, φάσης III κλινική δοκιμή, για την αξιολόγηση της αποτελεσματικότητας και της ασφάλειας ενός σκευάσματος λατανοπρόστης χωρίς συντηρητικό (YSLT) έναντι ενός φαρμάκου αναφοράς (Xalatan®) σε ασθενείς με πρωτογενές γλαύκωμα ανοικτής γωνίας (ΠΓΑΓ/POAG) ή οφθαλμική υπέρταση (ΟΥ/OHT) – Η Μελέτη COMET |
|
|
| Not yet recruiting | 3 | 170 | Europe | YSLT Latanoprost 50 μg/mL Eye Drop Solution, Xalatan 50 micrograms/mL Eye drops, solution, Eye drops, solution in single-dose container, Eye drops, solution, XALATAN | YONSUNG GMBH, YONSUNG GMBH | GLAUCOMA, OCCULAR HYPERTENSION Γλαύκωμα / Υψηλή πίεση στα μάτια, GLAUCOMA, OCCULAR HYPERTENSION Γλαύκωμα / Υψηλή πίεση στα μάτια, Diseases [C] - Eye Diseases [C11] | | | | |
2021-003387-27: COMPARATIVE TRIAL OF GENERIC LATANOPROST + TIMOLOL (50μG + 5MG)/ML EYE DROPS, SOLUTION (POLPHARMA S.A.) COMPARED TO XALACOM® (LATANOPROST 0.005 % OPHTHALMIC SOLUTION & TIMOLOL 0.5% FIXED COMBINATION, PFIZER) IN PATIENTS WITH OCULAR HYPERTENSION OR PRIMARY OPEN ANGLE GLAUCOMA. A generikus latanoproszt + timolol (50 μg + 5 mg)/ml oldatos szemcsepp (Polpharma S.A.) és a Xalacom® (latanoproszt 0,005% és timolol 0,5% fix kombinációs oldatos szemcsepp, Pfizer) összehasonlÃtó vizsgálata emelkedett szembelnyomású vagy primer nyÃlt zugú glaucomában szenvedÅ‘ betegeknél. |
|
|
| Ongoing | 3 | 40 | Europe | latanoprost + timolol (50 μg + 5 mg)/ml oldatos szemcsepp (Polpharma S.A.), preservative free, Xalacom® (latanoproszt 0,005% és timolol 0,5% fix kombinációs oldatos szemcsepp, Pfizer)., Eye drops, solution, Xalacom® | Pharmaceutical Works Polpharma S.A. (Polpharma S. A.), Polpharma S.A. | Ocular hypertension and open angle glaucoma, glaucoma zöldhályog, Diseases [C] - Eye Diseases [C11] | | | | |
NCT04133311 / 2017-004262-95: A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 3 | 386 | Europe | DE-130A, Catiolanze®, Xalatan®, DE-130A/DE-130A, Xalatan®/DE-130A | Santen SAS | Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease | 02/22 | 10/22 | | |
2021-005170-25: PHASE III MULTICENTER RANDOMIZED TRIAL OF PRESERVATIVE FREE LATANOPROST 50µG/ML VS XALATAN IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION Studio multicentrico randomizzato di confronto tra Latanoprost 50µg/ml senza conservanti verso Xalatan per il trattamento di pazienti con glaucoma ad angolo aperto o ipertensione oculare |
|
|
| Not yet recruiting | 3 | 110 | Europe | Latanoprost 50 microgrammi/ml, [2021-005170-25], Eye drops, solution | Genetic S.p.A. | Patients with Open-Angle Glaucoma or ocular hypertension Pazienti con Glaucoma ad angolo aperto o ipertensione oculare, Patients with Open-Angle Glaucoma or ocular hypertension Pazienti con Glaucoma ad angolo aperto o ipertensione oculare, Diseases [C] - Eye Diseases [C11] | | | | |
TC-002-301, NCT05165290: Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure |
|
|
| Active, not recruiting | 3 | 300 | US | Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005% | TearClear Corp | Elevated Intraocular Pressure | 09/22 | 09/22 | | |
Angel-J1, NCT05495061: A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 3 | 325 | Japan | STN1012600 ophthalmic solution 0.002%, Latanoprost ophthalmic solution 0.005% | Santen Pharmaceutical Co., Ltd. | Primary Open Angle Glaucoma, Ocular Hypertension | 04/23 | 04/23 | | |
Denali, NCT04630808: MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Active, not recruiting | 3 | 696 | US, RoW | NCX 470 0.1%, NCX 470, Latanoprost 0.005%, Latanoprost | Nicox Ophthalmics, Inc. | Open Angle Glaucoma, Ocular Hypertension | 03/25 | 07/25 | | |
NCT05583474: OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects |
|
|
| Recruiting | 3 | 240 | RoW | OPC-1085EL, OPC-1085EL ophthalmic solution, 0.005% Latanoprost, 0.005% Latanoprost ophthalmic solution | Otsuka Beijing Research Institute | Open Angle Glaucoma or Ocular Hypertension | 03/24 | 04/24 | | |
| Completed | 3 | 500 | US | Latanoprost, Xalatan, Bimatoprost, Lumigan, Travoprost, Travatan, Timolol, Timoptic, Dorzolamide, Trusopt, Brinzolamide, Azopt, Acetazolamide, Diamox, Methazolamide, Neptazane | University of Miami, National Eye Institute (NEI) | Glaucoma | 10/24 | 10/24 | | |
NCT06666855: A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China |
|
|
| Recruiting | 3 | 338 | RoW | DE-117B Eye Drops, Latanoprost | Santen Pharmaceutical Co., Ltd. | Open Angle Glaucoma, Ocular Hypertension | 03/26 | 03/26 | | |
NCT05513924: Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo. |
|
|
| Completed | 2/3 | 40 | RoW | Latanoprost 0.005% Ophthalmic Solution, Microneedling using Dr Pen Derma Pen Ultima A6®, 5Fluorouracil | South Valley University | Vitiligo | 11/22 | 12/22 | | |
2020-004836-93: Clinical study comparing the efficacy and safety of DE-126 with latanoprost in patients with glaucoma (high pressure inside the eye) |
|
|
| Ongoing | 2 | 40 | Europe | Xalatan 50 micrograms/mL eye drops, solution, DE-126, S01EE01, Eye drops, suspension in single-dose container, Ear/eye drops, solution, Xalatan 50 micrograms/mL eye drops, solution | SANTEN INCORPORATED, Santen Incorporated | Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT), Glaucoma, Body processes [G] - Ocular Physiological Phenomena [G14] | | | | |
NCT04448223: A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 |
|
|
| Recruiting | 2 | 100 | RoW | CKD-351, Latanoprost+Dorzolmamide | Chong Kun Dang Pharmaceutical | Primary Open Angle Glaucoma, Ocular Hypertension | 12/22 | 12/22 | | |
| Recruiting | 2 | 48 | US | QLS-111, 0.015%, QLS-111, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution, Vehicle, inactive control | Qlaris Bio, Inc. | Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma | 10/24 | 10/24 | | |
NCT04761705: Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Suspended | 1/2 | 70 | US | JV-GL1, Latanoprost 0.005% Ophthalmic Solution | JeniVision, Inc. | Ocular Hypertension, Open Angle Glaucoma | 03/25 | 07/25 | | |
NCT06239324: Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser |
|
|
| Recruiting | 1/2 | 70 | RoW | Latanoprost, fractional Erbium- YAG laser | Egymedicalpedia | Alopecia Areata | 04/24 | 05/24 | | |
NCT05790941: Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation |
|
|
| Recruiting | 1 | 12 | US | Latanoprost and Minoxidil | Aneira Pharma, Inc. | Hypotrichosis | 06/23 | 06/23 | | |
NCT04500574: Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension |
|
|
| Recruiting | 1 | 31 | US | Latanoprost eluting contact lens, Topical Latanoprost | Massachusetts Eye and Ear Infirmary, Harvard University | Glaucoma, Ocular Hypertension | 07/23 | 12/23 | | |
NCT05864885: Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia |
|
|
| Not yet recruiting | 1 | 14 | NA | Minoxidil, Latanoprost | Aneira Pharma, Inc., DataPharm Australia, CMAX Clinical Research, Agilex Australia | Androgenetic Alopecia | 07/23 | 07/23 | | |
NCT04060758: Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma |
|
|
| Active, not recruiting | 1 | 37 | RoW | PA5108 Latanoprost FA SR Ocular Implant, PA5108 | PolyActiva Pty Ltd | Open Angle Glaucoma | 09/24 | 02/25 | | |
NCT05935527: Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon |
|
|
| Completed | 1 | 50 | US | POLAT-001, Placebo, Normal Saline | Peregrine Ophthalmic | Lower Eyelid Steatoblepharon | 09/24 | 11/24 | | |
| Completed | 1 | 46 | RoW | Latanoprost (0.005%) | Zagazig University | Treatment Outcome | 08/24 | 08/24 | | |
NCT06730516: Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate |
|
|
| Completed | 1 | 56 | RoW | Latanoprost (Xalatan), Brimonidine 0.2 % | Zagazig University | Glaucoma | 09/24 | 10/24 | | |
ChiCTR1800015147: Measurement of the Rates of Retinal Nerve Fiber Layer Thinning to Guide Management of Myopic Glaucoma Patients |
|
|
| Suspended | N/A | 203 | | Phase I: latanoprost 0.005% vs brinzolamide1%/brimonidine 0.2%. Phase II: Additional IOP lowering by 20% vs. continued treatment. | The Chinese University of Hong Kong; Level of the institution：, General Research Fund | Myopic Glaucoma | | | | |
ChiCTR2000034631: Prospective study of the assessment of retinal microcirculation and structural changes of ocluar hypertension by optical coherence tomography angiography |
|
|
| Not yet recruiting | N/A | 165 | | latanoprost ;none ;none | Peking University Third Hospital; Peking University Third Hospital, Capital's Funds for Health Improvement and Research (No. CFH-2020-2-40911) | Ocular hypertension | | | | |
NCT04896125: Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study |
|
|
| Recruiting | N/A | 300 | RoW | Lumigan PF; Xalatan | National Taiwan University Hospital | Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders) | 08/22 | 08/22 | | |
